Core Insights - SPDR S&P Pharmaceuticals ETF (XPH) has returned 29.44% over the past year, significantly outperforming the S&P 500's 12% gain, but has only gained 10.49% over five years compared to the S&P 500's 74.77% [1] - The ETF's equal weighting structure amplifies the impact of clinical trial failures at smaller companies, leading to increased volatility [1] Performance Analysis - XPH's one-year performance reflects a strong rotation into pharmaceutical stocks driven by investor interest in drug development and pricing power narratives [1] - Over five years, XPH's return of 10.49% is dwarfed by the broader market's 74.77% gain, indicating that pharmaceutical stocks have not kept pace with technology and growth stocks [1] - The ten-year cumulative return for XPH is significantly lower than the S&P 500's 255.65% gain, highlighting that pharma-focused funds have historically acted as diversifiers rather than maximizing returns [1] Fund Structure and Strategy - XPH holds 57 positions with no single stock exceeding 2.12% of the portfolio, providing broad exposure to pharmaceutical companies without concentration risk [1] - The fund focuses 98.4% of its assets in healthcare, primarily in drug development and commercialization, avoiding exposure to device makers and insurers [1] - XPH has a lean cost structure with a 0.35% expense ratio and 45% annual turnover, but its 0.48% dividend yield makes it less attractive for income-focused investors [1] Market Context - Within the pharmaceutical ETF category, XPH's one-year return of 29.44% places it in the middle of the pack, with the iShares U.S. Pharmaceuticals ETF (IHE) achieving a 32.25% return [1] - The broader healthcare sector, which includes non-pharma exposure, returned only 10.59% over the past year, indicating that pure-play pharma funds benefited from sector rotation [1]

Market Overview - U.S. equities ended modestly higher, with the S&P 500 up 0.10% to 6,843.22, Nasdaq Composite up 0.14% to 22,578.38, and Dow Jones Industrial Average gaining 0.07% to 49,533.19, indicating a recovery from early-session weakness [1][2] Shift in Investor Focus - There is a notable shift in investor focus towards value stocks, which are often trading below their intrinsic value and offer a safety margin [2] Value Stock Evaluation - The Price to Cash Flow (P/CF) ratio is highlighted as an effective valuation metric for assessing value stocks, with companies like Harmony Biosciences Holdings, Tripadvisor, AES Corporation, and Concentrix Corporation showing low P/CF ratios [3][4] Financial Health Indicators - Positive cash flow is crucial as it indicates an increase in a company's liquid assets, allowing for debt settlement, expense management, reinvestment, and shareholder-friendly actions [6] Value Investing Strategy - A comprehensive investment strategy should include multiple metrics such as price-to-book ratio, price-to-earnings ratio, and price-to-sales ratio, along with a favorable Zacks Rank and Value Score to avoid value traps [7][11] Parameters for True-Value Stocks - Key parameters for selecting true-value stocks include P/CF less than or equal to industry median, price greater than or equal to $5, and average 20-day volume greater than 100,000 [8][10] Highlighted Value Stocks - Harmony Biosciences shows strong growth estimates with 21.4% sales and 25.9% EPS growth, while AES and Concentrix have posted earnings surprises and maintain strong Value Scores [9][14][16] Company Performance - Harmony Biosciences has a trailing four-quarter earnings surprise of 7.2% and a Value Score of A, with shares rising 4.6% in the past year [13][14] - Tripadvisor has a trailing four-quarter earnings surprise of 32.1%, with sales and EPS growth estimates of 2.6% and 44.1%, respectively, but shares have fallen 40.4% in the past year [15] - AES Corporation has a trailing four-quarter earnings surprise of 14.7%, with sales and EPS growth estimates of 3% and 0.9%, respectively, and shares have advanced 57.6% in the past year [16] - Concentrix Corporation has a trailing four-quarter earnings surprise of 1%, with sales and EPS growth estimates of 2.9% and 4.8%, respectively, but shares have declined 33.5% in the past year [17]

Moderna (MRNA) stock jumped more than 6% on Wednesday after the US Food and Drug Administration agreed to review the drugmaker's first flu shot of the season, reversing course on a decision to reject the review last week. Moderna recently developed a new flu vaccine using the same mRNA technique that underpins its COVID-19 vaccine. But after requesting review from the federal government, the FDA initially declined to review the drug — a necessary regulatory step toward bringing the drug to market — saying ...

Core Insights - Glencore traded more oil in 2025 but reported a decline in earnings from its energy trading business for the third consecutive year, attributed to well-supplied markets, geopolitical uncertainty, and softer market sentiment [1][1][1] Group 1: Trading Performance - Glencore's trading volumes increased to 4.2 million barrels per day, an 11% rise from the previous year, marking the highest level since 2020, although still below the 5.6 million bpd traded in 2017 [1][1][1] - The company experienced a significant rebound in the second half of 2025, following a weak first half where EBIT from energy marketing was only $40 million [1][1][1] Group 2: Financial Results - Earnings before interest and taxes from energy and steelmaking coal trading fell by 32% year-on-year to $614 million in 2025, a stark decline from a record high of $5.2 billion in 2022 [1][1][1] - Glencore announced a return of $2 billion to shareholders despite the drop in earnings [1][1][1] Group 3: Regulatory Developments - The U.S. Department of Justice ended its monitorship of Glencore's trading activities in March 2025, a year earlier than planned, following the company's agreement to pay fines related to bribery and market manipulation [1][1][1] - The monitorship had imposed a financial burden on Glencore, costing the company $85 million in 2024 alone [1][1][1]

Moderna Shares Rally 6% After FDA Reverses Decision Not To Review Flu Vaccinehttps://t.co/UVlS5k19Fn https://t.co/fTQGokWNL4 ...

Core Insights - Novo Nordisk has received European Commission approval for a new 7.2 mg once-weekly maintenance dose of Wegovy for adults with obesity, providing an additional treatment option for patients needing further weight reduction after the 2.4 mg dose [1][5] Group 1: Approval and Treatment Options - The 7.2 mg dose can be prescribed as three 2.4 mg injections during a single weekly session, with a regulatory application submitted for a dedicated 7.2 mg single-dose pen [2] - Wegovy is now available in all 27 EU member states in various strengths, including the newly approved 7.2 mg dose, and is already marketed in the UK [3] Group 2: Efficacy and Study Results - The phase III STEP UP study indicated that patients receiving the 7.2 mg dose achieved an average weight loss of 20.7% over 72 weeks, compared to 17.5% with the 2.4 mg dose [6][5] - Approximately 33.2% of patients on the 7.2 mg dose lost at least 25% of their weight, with most weight loss attributed to fat mass reduction while maintaining muscle function [7] Group 3: Safety and Tolerability - The safety profile of the 7.2 mg dose is consistent with the 2.4 mg dose, with common side effects being mild to moderate [8] Group 4: Market Context - Novo Nordisk shares have decreased by 9.9% over the past six months, contrasting with the industry's growth of 27.4% [4]

Key Takeaways Cytokinetics won EC approval for Myqorzo to treat adults with symptomatic obstructive HCM.Myqorzo showed significant pVO2 improvement in the phase III SEQUOIA-HCM study at 24 weeks.CYTK now has approvals in the U.S., EU and China, targeting a sizable oHCM market opportunity.Cytokinetics, Incorporated (CYTK) announced that the European Commission (EC) has approved Myqorzo (aficamten), 5 mg, 10 mg, 15 mg and 20 mg tablets, for the treatment of adult patients with symptomatic obstructive hypertro ...

Core Insights - Impax Asset Management's "Impax US Sustainable Economy Fund" reported a modest outperformance against the Russell 1000 benchmark, driven by sustainability-focused investments and specific stock gains, particularly in Health Care and Financials [1] - The Fund's Institutional Class achieved a total return of 16.00% in 2025, compared to 17.37% for the Russell 1000, influenced by sector allocation and company-level developments [1] - Management maintains a cautiously optimistic outlook, supported by falling interest rates, resilient corporate earnings, and ongoing investments in businesses benefiting from the transition to a sustainable economy [1] Company Highlights - Merck & Co., Inc. (NYSE:MRK) is highlighted for its strong performance in the biopharmaceutical sector, particularly through its oncology and immunology portfolio, with a notable contribution from the drug Keytruda [2][3] - The stock of Merck & Co., Inc. (NYSE:MRK) experienced a one-month return of 9.41%, with shares trading between $73.31 and $123.33 over the past 52 weeks, closing at approximately $121.57 on February 17, 2026, and a market capitalization of about $303.66 billion [2] - Merck's shares advanced due to strong sales of its oncology and immunology medications, with positive clinical trial results and an upward adjustment to 2026 earnings guidance boosting market confidence [3]

Core Viewpoint - Cosmos Health Inc. has significantly expanded its retail presence in the UK by launching its antimicrobial skin cleanser, C-Scrub, through Tesco, the largest retailer in the UK, enhancing the product's visibility and market credibility [1][3][6]. Group 1: Company Overview - Cosmos Health Inc. is a diversified, vertically integrated global healthcare group, incorporated in 2009 in Nevada, with a portfolio of proprietary pharmaceutical and nutraceutical brands [7]. - The company manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union through its subsidiary, Cana Laboratories S.A., which is licensed under European Good Manufacturing Practices (GMP) [7]. - Cosmos Health also distributes a wide range of pharmaceuticals and parapharmaceuticals, including branded generics and OTC medications, to retail pharmacies and wholesale distributors in Greece and the UK [7]. Group 2: Product Details - C-Scrub is a powerful antiseptic wash designed to reduce bacteria and help prevent infection, supporting effective skin hygiene [5]. - The product's entry into Tesco represents a pivotal moment for the company, enhancing its retail presence and credibility in the market [6]. Group 3: Market Strategy - Expanding distribution through Tesco is a meaningful advancement in Cosmos Health's UK growth strategy, expected to drive continued momentum for C-Scrub as the company strengthens retail partnerships [3][5]. - The CEO of Cosmos Health highlighted that this milestone not only provides immediate growth opportunities for C-Scrub but also establishes a platform for the potential rollout of additional products from the company's portfolio in the UK and broader European markets [6].

CHICAGO, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced a significant expansion of its United Kingdom (UK) retail footprint as its antimicrobial skin cleanser, C-Scrub Wash Chlorhexidine 4% (“C-Scrub”), is now available through Tesco, the UK’s largest retailer. Tesco is a leading multinational retail group operating across multiple markets and ranked among the top 20 retailer ...